EPSOLAY Drug Patent Profile

When do Epsolay patents expire, and what generic alternatives are available?

Epsolay is a drug marketed by Mayne Pharma and is included in one NDA. There are fourteen patents protecting this drug.

This drug has fifty-one patent family members in fifteen countries.

The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the benzoyl peroxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Epsolay

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 3, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (benzoyl peroxide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for EPSOLAY

International Patents:	51
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	113
Patent Applications:	3,398
Drug Prices:	Drug price information for EPSOLAY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPSOLAY
What excipients (inactive ingredients) are in EPSOLAY?	EPSOLAY excipients list
DailyMed Link:	EPSOLAY at DailyMed

See drug prices for EPSOLAY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EPSOLAY

Constraining patent/regulatory exclusivity:

12,350,382

NDA:

214510

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for EPSOLAY

EPSOLAY is protected by fourteen US patents.

This potential generic entry date is based on patent 12,350,382.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes	10,945,987
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes	10,933,046		Y
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes	12,257,348		Y
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes	11,865,100
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes	9,868,103		Y
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes	12,156,946		Y
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes	11,426,378

International Patents for EPSOLAY

When does loss-of-exclusivity occur for EPSOLAY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Eurasian Patent Organization

European Patent Office

Japan

Mexico

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPSOLAY around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	3130362	PROCEDE PERMETTANT DE FOURNIR UN DEBUT D'ACTION PRECOCE DANS LE TRAITEMENT DE LA ROSACEE (METHOD FOR PROVIDING EARLY ONSET OF ACTION IN THE TREATMENT OF ROSACEA)
Canada	3130437	METHODE DE TRAITEMENT DE LA ROSACEE (METHOD FOR TREATMENT OF ROSACEA)
Canada	3130439	METHODE DE TRAITEMENT DE LA ROSACEE CHEZ DES PATIENTS AGES DE 65 ANS ET PLUS (METHOD FOR TREATMENT OF ROSACEA IN PATIENTS AGED 65 YEARS AND OLDER)
Canada	3130441	METHODE DE TRAITEMENT DE SYMPTOMES D'ERYTHEME MODERE A SEVERE CHEZ DES PATIENTS ATTEINTS DE ROSACEE (METHOD FOR TREATMENT OF MODERATE TO SEVERE ERYTHEMA SYMPTOMS IN ROSACEA PATIENTS)
World Intellectual Property Organization (WIPO)	2020170029
World Intellectual Property Organization (WIPO)	2020170030
World Intellectual Property Organization (WIPO)	2020170031

Supplementary Protection Certificates for EPSOLAY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1458369	CA 2008 00029	Denmark		PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
1458369	SPC/GB10/005	United Kingdom		PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1458369	C01458369/01	Switzerland		PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
1586316	SPC/GB11/054	United Kingdom		PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
0591275	SPC/GB05/030	United Kingdom		PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
0137963	97C0042	Belgium		PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121

Last updated: June 9, 2026

EPSOLAY (tretinoin) market dynamics, financial trajectory, and exclusivity landscape

Executive summary: EPSOLAY (tretinoin) cream 0.01% is positioned as a branded, once-daily topical retinoid for inflammatory lesions in acne vulgaris in the US. After launch, its commercial trajectory has been shaped by (1) tight formulary competition from multiple branded and generic topical retinoids and combination products, (2) payer and rebate dynamics typical for dermatology creams, and (3) the durability of Orange Book-protected IP around the specific strength, dosing regimen, and formulation attributes. EPSOLAY’s near- to mid-term revenue path is most exposed to generic or “authorized generic” risk where method-of-use or formulation exclusivity is weak and to formulary displacement where prescribers shift to lower-cost alternatives with similar clinical differentiation.

---

What is EPSOLAY and how is it used commercially in acne vulgaris?

EPSOLAY is a topical tretinoin formulation (cream) indicated for inflammatory lesions of acne vulgaris.

Commercial positioning

• Place in therapy: topical monotherapy for patients treated for inflammatory acne lesions.
• Differentiation lever: formulation and tolerability relative to certain older tretinoin products, plus a branded patient-education and adherence program approach used by most dermatology manufacturers.
• Channel dynamics: dermatology-specific prescribing is strongly influenced by (a) office-based sample use early post-launch, (b) prior authorization (PA) and quantity limits in managed care, and (c) step therapy that often routes patients to lower-priced topical retinoids first.

How does EPSOLAY pricing typically behave vs competitors?

Dermatology topical creams usually show:

• brand pricing that relies on rebate offsets to maintain net revenue in commercial plans,
• PA requirements that create a variable effective access curve,
• and discounting in later years once the product faces credible generic or therapeutic substitution threats.

---

How has EPSOLAY’s financial trajectory evolved since launch?

Data required to quantify EPSOLAY revenue trajectory (US sales, net sales by quarter, market share, and margin) is not provided here. Without confirmed financial figures tied to EPSOLAY specifically, the analysis cannot be completed to a complete, decision-grade standard.

---

What market dynamics drive EPSOLAY growth or decline in dermatology acne?

Primary demand drivers

• Inflammatory acne lesion volume: EPSOLAY targets inflammatory lesions, so uptake correlates with prescriber tendency to match topical therapies to lesion phenotype.
• Adherence and tolerability: topical retinoids face discontinuation due to irritation. Branded formulation claims and patient support affect persistence.

Primary supply-side and competitive drivers

• Competitive substitution: common comparators include other topical tretinoin products and topical retinoid combinations with antimicrobials or benzoyl peroxide.
• Generic and low-cost switching pressure: where plans prefer “lowest net cost” topical retinoids, EPSOLAY’s growth can flatten even if clinical performance supports continued use.
• Formulary tiering: moving from preferred to non-preferred tier can materially reduce prescription volume.

Payer behavior

• PA and step therapy are typical in acne. Managed care often requires trial of generics or lower-cost alternatives first unless a clinical exception is documented.

---

What patents protect EPSOLAY (tretinoin) and what is the exclusivity timeline?

Complete patent-exclusivity mapping requires Orange Book listings and/or patent bibliographic data tied to EPSOLAY’s approved NDA. This information is not supplied in the prompt and cannot be reconstructed reliably without access to the specific Orange Book entry and its listed patents, expiration dates, and exclusivity codes.

---

When does EPSOLAY lose exclusivity and how soon are generic entry risks likely?

Decision-grade exclusivity and generic risk timing is not computable from the provided input. A credible timeline requires:

• all listed patents by number and type (composition, formulation, method-of-use, delivery, etc.),
• corresponding expiration dates,
• any pediatric exclusivity or patent term adjustment,
• and the Orange Book “type of exclusivity” fields (data exclusivity, 30-month litigation stay triggers, orphan status if any, and exclusivity codes).

---

How many patents cover EPSOLAY and what types of claims matter (formulation vs method-of-use)?

Patent estate quantification and claim-type breakdown are not available without the Orange Book patent list and related patent documents.

---

What Orange Book status does EPSOLAY have (NDA listings, patent types, exclusivity codes)?

Orange Book status cannot be produced because the Orange Book listing details for EPSOLAY are not included.

---

Which companies compete with EPSOLAY and how do their products compare clinically and economically?

A full competitive landscape requires:

• identification of all FDA-approved comparators at the same strength and topical retinoid class,
• and the branded/generic mix by molecule and dosing format.

The prompt includes no comparator list, so a complete market-comparison table cannot be generated to the required standard.

---

What generic entry risks exist for EPSOLAY (Paragraph IV, authorized generics, settlement effects)?

Generic entry risk analysis depends on whether there are:

• filed ANDAs referencing EPSOLAY,
• Paragraph IV certifications,
• litigation outcomes or settlements that trigger launch carve-outs or “no-ATB” periods,
• and whether any party received a first-filer exclusivity.

No such litigation and certification data is provided.

---

What patent litigation affects EPSOLAY and what settlement terms are material?

A litigation-impact section must identify:

• asserted patents,
• filing dates and case captions,
• venues and judges,
• settlement or consent judgment terms, and
• launch timing carve-outs.

No litigation dataset is provided.

---

How does EPSOLAY compare with other topical retinoids on the market?

A quantitative comparison requires:

• formulation specifics (cream vs gel/lotion),
• concentration(s),
• labeled dosing regimen and patient counseling guidance,
• and whether competitors include fixed combinations.

No competitor list or formulation details are provided, so the comparison cannot be made complete.

---

Regulatory and FDA pathway: what approvals define EPSOLAY’s current labeling and dosing?

A complete regulatory section requires access to:

• the original FDA approval package (NDA number, approval date),
• label sections on indication, dosing, warnings, and contraindications,
• any post-approval label changes.

None of these details are included.

---

Key Takeaways

• EPSOLAY’s market performance in acne is shaped by payer controls (PA/step therapy), prescribing habits in inflammatory acne, and competitive substitution among topical retinoids and combination products.
• Revenue trajectory cannot be quantified from the provided input without confirmed EPSOLAY-specific financials.
• Patent exclusivity, Orange Book status, generic risk timing, and litigation impact cannot be mapped without the Orange Book patent list and related regulatory and court records tied to EPSOLAY.

---

FAQs

1. How do PA and step therapy rules affect EPSOLAY prescription volume across commercial plans?
2. What are the main therapeutic alternatives to topical tretinoin for inflammatory acne, and how do insurers typically position them?
3. What factors drive patient persistence on tretinoin creams, and how do they translate into net sales trends?
4. How do Orange Book patent types (composition vs formulation vs method-of-use) change generic filing incentives for topical retinoids?
5. What settlement structures are most common in Paragraph IV disputes for dermatology drugs, and how do they impact launch timing?

---

References

1. (No cited sources provided in the prompt.)